表紙
市場調查報告書

多發性硬化症(MS) - 市場洞察,流行病學,市場預測 ∼2027年

Multiple Sclerosis - Market Insight, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 602106
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性硬化症(MS) - 市場洞察,流行病學,市場預測 ∼2027年 Multiple Sclerosis - Market Insight, Epidemiology and Market Forecast - 2028
出版日期: 2019年01月01日內容資訊: 英文 100 Pages
簡介

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的多發性硬化症(MS)市場調查,市場及疾病概要,病型、年齡、綜合障礙度、性別的患病數的變化與預測,各國市場趨勢,上市藥及開發中的治療藥概要,市場成長要素及障礙分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 重要的洞察

第2章 多發性硬化症(MS)市場概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第3章 多發性硬化症(MS):疾病背景和概要

  • 簡介
  • 症狀
  • 病型
  • 風險因素
  • 原因
  • 病因
  • 診斷

第4章 流行病學和患者人口

  • 主要的觀察
  • 人口與預測參數
  • 主要7個國家的患病數
  • 主要7個國家的患病數:各地區
  • 主要7個國家的患病數(實數)
  • 主要7個國家的患病數(預測數)

第5章 美國的多發性硬化症(MS)市場

  • 美國
    • 患病數
    • 患病數:性別
    • 患病數:病型
    • 患病數:各年齡
    • 患病數:各綜合障礙度(EDSS)

第6章 歐盟5國的多發性硬化症(MS)市場

  • 德國
    • 患病數
    • 患病數:性別
    • 患病數:病型
    • 患病數:各年齡
    • 患病數:各綜合障礙度(EDSS)
  • 法國
    • 患病數
    • 患病數:性別
    • 患病數:病型
    • 患病數:各年齡
    • 患病數:各綜合障礙度(EDSS)
  • 義大利
    • 患病數
    • 患病數:性別
    • 患病數:病型
    • 患病數:各年齡
    • 患病數:各綜合障礙度(EDSS)
  • 西班牙
    • 患病數
    • 患病數:性別
    • 患病數:病型
    • 患病數:各年齡
    • 患病數:各綜合障礙度(EDSS)
  • 英國
    • 患病數
    • 患病數:性別
    • 患病數:病型
    • 患病數:各年齡
    • 患病數:各綜合障礙度(EDSS)

第7章 日本的多發性硬化症(MS)市場

  • 患病數
  • 患病數:性別
  • 患病數:病型
  • 患病數:各年齡
  • 患病數:各綜合障礙度(EDSS)

第8章 治療

  • 英國神經學會:多發性硬化症(MS)修訂指南

第9章 未滿足需求

第10章 已上市治療藥

  • Betaferon:Bayer Healthcare
    • 醫藥品簡介
    • 作用機制
    • 法規的里程碑
    • 優點與缺點
    • 安全性和有效性
    • 產品簡介
  • Rebif:Merck KGA
  • Copaxone:Teva Pharmaceutical
  • Avonex:Biogen Idec. Limited
  • Tysabri:Biogen Idec. Limited
  • Fampyra/Ampyra:Acorda Therapeutics/ Biogen Idec Ltd.
  • Gilenya:Novartis
  • Aubagio:Genzyme
  • Tecfidera:Biogen Idec Ltd.
  • Plegridy:Biogen Idec Ltd.
  • Lemtrada:Genzyme
  • Zinbryta:Biogen Idec
  • Ocrevus:Genentech
  • Mavenclad:Merck

第11章 新藥

  • Key Cross Competition
  • 第三階段試驗藥
    • ALKS 8700:Biogen
    • Ublituximab:TG Therapeutics
    • Ozanimod:Celgene Corporation
    • OMB157:Novartis
    • MD1003:MedDay Pharma
    • Masitinib:AB Science
    • Siponimod:Novartis
    • Ponesimod:Johnson & Johnson
    • Evobrutinib:Merck
    • ADS-5102:Adamas Pharmaceuticals

第12章 主要7個國家市場分析

  • 主要的觀察

第13章 市場規模的變化與預測:各國

  • 市場規模:各治療藥物
  • 市場佔有率:各給藥途徑
  • 市場佔有率:各給藥途徑

第14章 美國市場預測

  • 市場規模:各治療藥物

第15章 歐盟5國市場預測

  • 市場規模:各治療藥物

第16章 日本市場預測

  • 市場規模:各治療藥物

第17章 成本分析

第18章 競爭情形

第19章 市場成長要素

第20章 市場障礙

第21章 附錄

  • 調查方法

第22章 DelveInsight的服務內容

第23章 免責聲明

第24章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0319

DelveInsight's "Multiple Sclerosis - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Multiple Sclerosis epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Multiple Sclerosis Understanding and Treatment Algorithm

The market report provides the overview of the Multiple Sclerosis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Multiple Sclerosis Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Multiple Sclerosis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Multiple Sclerosis Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Multiple Sclerosis Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Multiple Sclerosis market.

Multiple Sclerosis Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Multiple Sclerosis Report Insights

  • Patient Population in Multiple Sclerosis
  • Therapeutic Approaches in Multiple Sclerosis
  • Multiple Sclerosis Pipeline Analysis
  • Multiple Sclerosis Market Size and Trends
  • Multiple Sclerosis Market Opportunities
  • Impact of upcoming Therapies in Multiple Sclerosis

Multiple Sclerosis Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Multiple Sclerosis Report Assessment

  • Current Treatment Practices in Multiple Sclerosis
  • Unmet Needs in Multiple Sclerosis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Multiple Sclerosis market
  • Organize sales and marketing efforts by identifying the best opportunities for Multiple Sclerosis market
  • To understand the future market competition in the Multiple Sclerosis market.

Table of Contents

1. Report Introduction

2. Multiple Sclerosis Market Overview at a Glance

  • 2.1. Market Share Distribution of Multiple Sclerosis in 2016
  • 2.2. Market Share Distribution of Multiple Sclerosis in 2028

3. Disease Background and Overview: Multiple Sclerosis

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Multiple Sclerosis in 7MM
  • 4.3. Total Prevalent Patient Population of Multiple Sclerosis in 7MM - By Countries

5. Epidemiology of Multiple Sclerosis by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.1.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.1.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.1.5. Diagnosed Cases of the Multiple Sclerosis
    • 5.1.6. Treatable Cases of the Multiple Sclerosis
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.4.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.4.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.4.5. Diagnosed Cases of the Multiple Sclerosis
    • 5.4.6. Treatable Cases of the Multiple Sclerosis
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.5.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.5.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.5.5. Diagnosed Cases of the Multiple Sclerosis
    • 5.5.6. Treatable Cases of the Multiple Sclerosis
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.6.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.6.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.6.5. Diagnosed Cases of the Multiple Sclerosis
    • 5.6.6. Treatable Cases of the Multiple Sclerosis
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.7.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.7.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.7.5. Diagnosed Cases of the Multiple Sclerosis
    • 5.7.6. Treatable Cases of the Multiple Sclerosis
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.8.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.8.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.8.5. Diagnosed Cases of the Multiple Sclerosis
    • 5.8.6. Treatable Cases of the Multiple Sclerosis
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Multiple Sclerosis
    • 5.9.3. Sub-Type Specific cases of the Multiple Sclerosis *
    • 5.9.4. Sex- Specific Cases of the Multiple Sclerosis *
    • 5.9.5. Diagnosed Cases of the Multiple Sclerosis
    • 5.9.6. Treatable Cases of the Multiple Sclerosis

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Multiple Sclerosis

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Multiple Sclerosis

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Multiple Sclerosis : 7MM Market Analysis

  • 12.1. 7MM Market Size of Multiple Sclerosis
  • 12.2. 7MM Percentage Share of drugs marketed for Multiple Sclerosis
  • 12.3. 7MM Market Sales of Multiple Sclerosis by Products

13. Multiple Sclerosis : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Multiple Sclerosis in United States
    • 13.1.2. Percentage Share of drugs marketed for Multiple Sclerosis in United States
    • 13.1.3. Market Sales of Multiple Sclerosis by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Multiple Sclerosis in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Multiple Sclerosis in Germany
      • 13.2.1.3. Market Sales of Multiple Sclerosis by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Multiple Sclerosis in France
      • 13.2.2.2. Percentage Share of drugs marketed for Multiple Sclerosis in France
      • 13.2.2.3. Market Sales of Multiple Sclerosis by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Multiple Sclerosis in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Multiple Sclerosis in Italy
      • 13.2.3.3. Market Sales of Multiple Sclerosis by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Multiple Sclerosis in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Multiple Sclerosis in Spain
      • 13.2.4.3. Market Sales of Multiple Sclerosis by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Multiple Sclerosis in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Multiple Sclerosis in United Kingdom
      • 13.2.5.3. Market Sales of Multiple Sclerosis by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Multiple Sclerosis in Japan
    • 13.3.2. Percentage Share of drugs marketed for Multiple Sclerosis in Japan
    • 13.3.3. Market Sales of Multiple Sclerosis by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Multiple Sclerosis in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Multiple Sclerosis in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Multiple Sclerosis in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Multiple Sclerosis in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Multiple Sclerosis in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Multiple Sclerosis in United States (2016-2028)
  • Table 7: Treatable Cases of the Multiple Sclerosis in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Multiple Sclerosis in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Table 12: Treatable Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Multiple Sclerosis in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Multiple Sclerosis in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Multiple Sclerosis in France (2016-2028)
  • Table 16: Diagnosed Cases of the Multiple Sclerosis in France (2016-2028)
  • Table 17: Treatable Cases of the Multiple Sclerosis in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Multiple Sclerosis in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Table 22: Treatable Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Multiple Sclerosis in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Table 27: Treatable Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Multiple Sclerosis in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Multiple Sclerosis in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Multiple Sclerosis in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Multiple Sclerosis in UK (2016-2028)
  • Table 32: Treatable Cases of the Multiple Sclerosis in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Multiple Sclerosis in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Multiple Sclerosis in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Multiple Sclerosis in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Multiple Sclerosis in Japan (2016-2028)
  • Table 37: Treatable Cases of the Multiple Sclerosis in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Table 42:7MM- Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Table 45: United States-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Table 48: Germany-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Table 51: France-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Table 54: Italy-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Table 57: Spain-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Table 60:UK-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Table 63: Japan-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Multiple Sclerosis in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Multiple Sclerosis in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Multiple Sclerosis in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Multiple Sclerosis in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Multiple Sclerosis in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Multiple Sclerosis in United States (2016-2028)
  • Figure 7: Treatable Cases of the Multiple Sclerosis in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Multiple Sclerosis in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Multiple Sclerosis in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Multiple Sclerosis in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Multiple Sclerosis in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Multiple Sclerosis in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Multiple Sclerosis in France (2016-2028)
  • Figure 17: Treatable Cases of the Multiple Sclerosis in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Multiple Sclerosis in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Multiple Sclerosis in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Multiple Sclerosis in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Multiple Sclerosis in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Multiple Sclerosis in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Multiple Sclerosis in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Multiple Sclerosis in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Multiple Sclerosis in UK (2016-2028)
  • Figure 32: Treatable Cases of the Multiple Sclerosis in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Multiple Sclerosis in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Multiple Sclerosis in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Multiple Sclerosis in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Multiple Sclerosis in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Multiple Sclerosis in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Figure 45: United States-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Figure 51: France-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Figure 60:UK-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Multiple Sclerosis in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Multiple Sclerosis by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Multiple Sclerosis by Therapies in USD MM (2016-2028)
Back to Top